Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years

Haemophilia : the Official Journal of the World Federation of Hemophilia
K VepsäläinenJ Martikainen

Abstract

For previously untreated patients (PUPs) with severe haemophilia A in Finland for the past 2 decades, the standard practice has been to start early primary prophylaxis. We evaluated the long-term clinical outcomes and costs of treatment with high-dose prophylaxis in PUPs from birth to adolescence, including immune tolerance induction (ITI). From the medical records of all PUPs born between June 1994 and May 2013 in Finland, we retrospectively extracted data on clinical outcomes and healthcare use. Using linear mixed models, we analysed longitudinal clinical outcome data. To analyse skewed cost data, including zero costs, we applied hurdle regression. All 62 patients received early regular prophylaxis; totally, they have had treatment for nearly 700 patient-years. The median age of starting home treatment was 1.1 years. The mean (SD) annual treatment costs (€ per kg) were 4391€ (3852). For ages 1-3, ITI comprised over half of the costs; in other groups, prophylactic FVIII treatment dominated. With these high costs, however, clinical outcomes were desirable; median (IQR) ABR was low at 0.19 (0.07-0.46) and so was AJBR at 0.06 (0-0.24). Thirteen (21%) patients developed a clinically significant inhibitor, 10 (16%) with a high titr...Continue Reading

References

Jul 1, 1992·Journal of Internal Medicine·I M NilssonH Pettersson
Sep 27, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·K Steen CarlssonB Lindgren
Sep 11, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·G AuerswaldR Zimmermann
Sep 11, 2004·Haemophilia : the Official Journal of the World Federation of Hemophilia·K Steen CarlssonB Lindgren
Apr 22, 2005·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Aug 10, 2007·The New England Journal of Medicine·Marilyn J Manco-JohnsonBruce L Evatt
Mar 15, 2008·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·S S TanL Hakkaart-van Roijen
Apr 22, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·N RisebroughB M Feldman
Nov 3, 2009·Journal of Thrombosis and Haemostasis : JTH·S SchulmanUNKNOWN Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on T
Dec 8, 2009·Basic & Clinical Pharmacology & Toxicology·Kari FuruHenrik Toft Sørensen
Feb 13, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·A TagliaferriG Castaman
Jan 25, 2011·Journal of Thrombosis and Haemostasis : JTH·A GringeriUNKNOWN ESPRIT Study Group
Nov 3, 2011·Haemophilia : the Official Journal of the World Federation of Hemophilia·L A ValentinoM P Luo
Nov 22, 2011·Blood·Charles R M HayUNKNOWN International Immune Tolerance Study
Jun 5, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·E BerntorpR Pérez
Jan 3, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·L H SchrijversK Fischer
Apr 5, 2013·Blood·Samantha C GouwUNKNOWN PedNet and Research of Determinants of INhibitor development (RODIN) Study Group
Dec 21, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·J IngerslevO P Plyushch
Jul 26, 2014·Journal of Thrombosis and Haemostasis : JTH·V S BlanchetteA Srivastava
Feb 18, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·S R EarnshawC M Kessler
Apr 3, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·K VepsäläinenP Riikonen
Jun 3, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·L A ValentinoUNKNOWN International Immune Tolerance Induction Study Investigators
Oct 20, 2015·Seminars in Thrombosis and Hemostasis·Victor S Blanchette, Alok Srivastava
May 18, 2016·Journal of Thrombosis and Haemostasis : JTH·K FischerV S Blanchette
Jun 25, 2016·Haemophilia : the Official Journal of the World Federation of Hemophilia·K VepsäläinenP Riikonen
Jul 12, 2016·Haemophilia : the Official Journal of the World Federation of Hemophilia·A NijdamK Fischer

❮ Previous
Next ❯

Citations

Jan 15, 2020·Expert Review of Hematology·E Carlos Rodriguez-Merchan
Jul 1, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Hae Kyung KimCarlos Rubio-Terrés
Nov 21, 2020·Haemophilia : the Official Journal of the World Federation of Hemophilia·Hanna VentolaRiitta Lassila

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Haemophilia : the Official Journal of the World Federation of Hemophilia
K VepsäläinenP Riikonen
Haemophilia : the Official Journal of the World Federation of Hemophilia
S L MeeksA L Dunn
Haemophilia : the Official Journal of the World Federation of Hemophilia
P C Ter AvestE P Mauser-Bunschoten
Haemophilia : the Official Journal of the World Federation of Hemophilia
N EwingW Kreuz
© 2022 Meta ULC. All rights reserved